Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Preclinical Data

October 8, 2026

Antengene to Present Latest Preclinical Results of ATG-207 (CD3-TGF Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Oct. 8, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for… Source: Read More

Announcements

Antengene Corp Ltd, Bifunctional Fusion Protein, CD3-TGF, clinical trials, pr-newswire, Preclinical Data
January 15, 2026

Centessa Pharmaceuticals Expands Orexin Receptor Pipeline into Neuropsychiatric Territory

NASDAQ: $CNTA Centessa Pharmaceuticals recently made a significant announcement regarding the expansion of its pipeline, specifically leveraging its Orexin Receptor 2 (OX2R) agonist program. A press release detailed plans for a poster presentation at an upcoming scientific meeting, showcasing new preclinical data that supports moving these compounds into development for neuropsychiatric indications. For those unfamiliar,…

Conferences

$CNTA, Centessa Pharmaceuticals, Neuropsychiatric, OX2R Agonist, Pipeline Expansion, Preclinical Data

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Buy A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS, buy a premium report below with longer outlooks, allowing you to discover earlier trade entries. Get positioned BEFORE a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

Get FREE Biotech Stock Catalyst Reports

Email